98%
921
2 minutes
20
Primary Objective: A randomized study to compare the induction abortion interval (IAI) using two different routes of Low-dose misoprostol administration Sublingual (S/L) and vaginal, after priming with two sequential doses of mifepristone for second-trimester medical abortion.
Study Design: After randomization in two groups, participants received two doses of mifepristone (200 mg) 24 h apart. On day 3, 200mcg of misoprostol was given by S/L route to group 1 and by vaginal route to group 2, (400mcg among women with gestation ≤16 weeks) and every 6 hours for a maximum of 3 doses.
Results: The mean IAI (13.71±8.55 h and 13.22±8.22 h; =0.768), mean number of misoprostol doses (2.08±1.08 and 2.54±1.12, =0.05) and mean misoprostol dose (453.9±224.93 and 492.31±208.23 mcg, =0.409) was similar. The complete abortion rate after 24 h (77.5% vs 87.5%, =0.23), after 48 h (95% vs 97.5%, =1.00) and minimal untoward effects seen were all similar in the two groups.
Conclusions: Both SL and vaginal routes of misoprostol, after two doses of mifepristone were equally effective. The mean cumulative doses of misoprostol were similar, and a complete abortion rate of > 95% at 48 h was achieved with either route..
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/13625187.2025.2452178 | DOI Listing |
Reprod Fertil
July 2025
Department of Animal Biology and Physiology, Faculty of Science, University of Yaoundé 1, Yaoundé, Cameroon.
Abstract: Over the past 30 years, the number of new cases of uterine leiomyomas (UL) in women of reproductive age has increased by 67.14% worldwide. The limitations of the current therapeutic options have led to the search for alternatives.
View Article and Find Full Text PDFJ Obstet Gynaecol Can
June 2025
Department of Obstetrics and Gynaecology, University of Toronto, Toronto, ON; Department of Obstetrics and Gynecology, North York General Hospital, Toronto, ON.
Objectives: This prospective single-arm study was conducted to understand the expulsion rate of the gestational sac in the management of early pregnancy loss (EPL).
Methods: We recruited 441 participants; 188 met the eligibility criteria. Participants were 18 years of age and older who experienced a confirmed EPL (<12 weeks gestational age) defined by an intrauterine pregnancy with a non-viable embryonic or anembryonic gestational sac with no fetal heart activity.
J Clin Med
June 2025
San Giovanni di Dio Ruggi d'Aragona Scuola Medica Salernitana, UOC Obstetrics and Gynecology Azienda Ospedaliera Universitaria, Via San Leonardo, 84131 Salerno, Italy.
The objective of this review is to demonstrate the efficacy of mifepristone as an inducing agent of labor by analyzing its impact on cervical maturation and maternal and neonatal outcomes. The research results showed that mifepristone facilitates cervical ripening and enhances uterine sensitivity. : A narrative review of the literature was conducted to descriptively summarize and compare available data.
View Article and Find Full Text PDFJ Pharm Bioallied Sci
May 2025
Department of Pathology, Nandkumar Singh Chouhan Government Medical College, Khandwa, Madhya Pradesh, India.
Background: Mifepristone results in cervical ripening in females undergoing pregnancy termination. It causes cervical ripening via blockage of progesterone receptors.
Aim: The present study aimed to assess the safety and efficacy of oral Mifepristone for cervical ripening in single-live intrauterine term unscarred pregnancies.
Eur J Obstet Gynecol Reprod Biol
July 2025
Department of Obstetrics and Gynecology, Carmel Lady Davis Medical Center, Haifa, Israel; The Rappaport Faculty of Medicine, Technion - Haifa, Israel.
Objective: To evaluate the risk factors for procedural extraction of retained products of conception after pharmacological treatment for early pregnancy loss.
Methods: A retrospective cohort study of patients with early pregnancy loss treated with vaginal misoprostol between November 1, 2012, and March 31, 2018, compared to patients treated with Mifepristone and misoprostol co-treatment between May 1, 2018, and February 28, 2023, who subsequently underwent a procedural intervention due to retained products of conception.
Results: We identified 429 patients treated with misoprostol monotherapy and 418 treated with mifepristone-misoprostol co-treatment.